Showing 108 news articles about PrEP science

Filters Content type: Editors' picks Topic: PrEP science

Research, news and information on the effectiveness of oral pre-exposure prophylaxis (PrEP) and its impact on HIV epidemics, as well as clinical issues for PrEP users.

Pharmaceutical industry

GSK's ViiV, touting superior long-acting data, can challenge Gilead in HIV prevention: analyst

Editor's pick
FiercePharma
13 July 2020
PrEP science

The Dangers of Excluding Women From HIV Prevention Drug Tests

Editor's pick
WIRED
10 June 2020
PrEP science

Kaiser study shows no new HIV cases among PrEP 2-1-1 users

Editor's pick
Bay Area Reporter
9 June 2020
Adherence

OraSure to Buy UrSure, an HIV Startup That Tests Adherence to PrEP

Editor's pick
POZ
4 June 2020
PrEP policies & guidelines

Sex—and PrEP—During the Pandemic

Editor's pick
POZ
3 June 2020
PrEP science

Long-Acting Injectable Cabotegravir for HIV Pre-Exposure Prophylaxis (PrEP): Promising Results from HPTN 083

Editor's pick
TAG
21 May 2020
PrEP science

Long-acting injectable drug prevents HIV infections

Editor's pick
Science
18 May 2020
PrEP science

Global HIV prevention study to stop early after ViiV Healthcare’s long-acting injectable formulation of cabotegravir dosed every two months shows higher efficacy than daily oral PrEP

Editor's pick
ViiV press release
18 May 2020
PrEP science

F/TAF and F/TDF Efficacy and Safety as PrEP for 96 Weeks

Editor's pick
NATAP
20 March 2020
PrEP science

NIH study finds lower concentration of PrEP drug in pregnant teens & young women

Editor's pick
National Institutes of Health
10 March 2020
PrEP science

Uptick in Statin Use After Descovy in HIV PrEP

Editor's pick
Medscape (requires free registration)
9 March 2020
PrEP science

Researchers launch study to assess safety of PrEP and dapivirine ring in pregnant women

Editor's pick
EurekAlert
11 February 2020
Bad science & bogus treatments

Facebook disables some misleading ads on HIV prevention drugs, responding to growing outcry

Editor's pick
Washington Post
2 January 2020
PrEP science

Facebook ads push misinformation about HIV prevention drugs, LGBT activists say, ‘harming public health’

Editor's pick
Washington Post
10 December 2019
HIV treatment

Top 10 HIV Clinical Developments of 2019

Editor's pick
TheBodyPro
27 November 2019
Government, leadership & policy

The World Cannot End HIV Without Continued Innovation

Editor's pick
POZ
25 November 2019
New & experimental HIV treatments

ViiV Healthcare announces exclusive licensing agreement with the National Institutes of Health for investigational "bNAb" with potential for long-acting HIV treatment and prevention

Editor's pick
ViiV Healthcare press release
21 November 2019
PrEP science

Descovy for PrEP Continues to Be Noninferior to Truvada, According to 96 Week Data

Editor's pick
Monthly Prescribing Reference
8 November 2019
PrEP science

Future PrEP Drugs, Delivery Methods, Technologies Target Adherence Issue

Editor's pick
American Journal of Managed Care
1 November 2019
PrEP science

Where Were the Women? Gender Parity in Clinical Trials

Editor's pick
New England Journal of Medicine (free registration required)
31 October 2019
PrEP science

Evaluating Microarray Patches for Long-Acting PrEP and Contraceptives

Editor's pick
Contagion Live
3 October 2019
Injectable & long-acting HIV treatment

HIV implant targets disease for up to a year

Editor's pick
The Engineer
26 September 2019
PrEP science

Long-acting injectable multi-drug implant shows promise for HIV prevention and treatment

Editor's pick
EurekAlert
23 September 2019
PrEP policies & guidelines

A New Oral PrEP Strategy Is On the Horizon, But Who’s Going to Get It?

Editor's pick
AVAC
29 August 2019